US Dollar vs MXN

Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

Regístrate

JNJ Johnson and Johnson

165.84

0.00 (0.00%)

31 Mar 2025 - Cerrado

Retrasado por 15 minutos

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025

Haga Click aquí para más Gráficas Johnson and Johnson.

Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025

Haga Click aquí para más Gráficas Johnson and Johnson.

Noticias sobre Johnson and Johnson JNJ

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
Lunes 31 de Marzo 2025 (5 horas hace) • Business Wire

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Miércoles 26 de Marzo 2025 (6 días hace) • PR Newswire (US)

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
Miércoles 26 de Marzo 2025 (6 días hace) • PR Newswire (US)

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
Viernes 21 de Marzo 2025 (2 semanas hace) • Business Wire

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
Jueves 20 de Marzo 2025 (2 semanas hace) • PR Newswire (US)

Form PX14A6G - Notice of exempt solicitation submitted by non-management
Jueves 20 de Marzo 2025 (2 semanas hace) • Edgar (US Regulatory)

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Jueves 20 de Marzo 2025 (2 semanas hace) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 19 de Marzo 2025 (2 semanas hace) • Edgar (US Regulatory)

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
Martes 18 de Marzo 2025 (2 semanas hace) • PR Newswire (US)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Miércoles 12 de Marzo 2025 (3 semanas hace) • Edgar (US Regulatory)

Form ARS - Annual Report to Security Holders
Miércoles 12 de Marzo 2025 (3 semanas hace) • Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements
Miércoles 12 de Marzo 2025 (3 semanas hace) • Edgar (US Regulatory)

Más de Johnson and Johnson Artículos de Noticias

Armac Locacao Logistica ... ON

Dexxos Participacoes S.A PN

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones